Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 11:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 3,785 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Active, not recruiting Phase 1Phase 2 Interventional

Carfilzomib and Belatacept for Desensitization

NCT05017545
Conditions
Highly Sensitized Prospective Kidney Transplant Recipients
Interventions
carfilzomib, belatacept, Bone marrow aspiration
Biological · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Completed No phase listed Observational Accepts healthy volunteers

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795
Conditions
Non Small-cell Lung Cancer
Interventions
Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Respiratory Syncytial Virus
Interventions
Nasal swab sampling, Blood sampling, Diary cards
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 6 Years
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
9
States / cities
Oakland, California • Sacramento, California • Santa Clara, California + 5 more
Conditions
Osteosarcoma, Ewing Sarcoma
Interventions
Eflornithine, Topotecan, Cyclophosphamide, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Cisplatin, Methotrexate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
0 Years to 50 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Tampa, Florida • Portland, Oregon • Hershey, Pennsylvania
Conditions
Liver Diseases, Portal Hypertension
Interventions
SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
X-linked Severe Combined Immunodeficiency (XSCID)
Interventions
Campath, Palifermin, Busulfan, Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glioblastoma
Interventions
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
Drug
Lead sponsor
SignPath Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Educational Intervention, Minorities
Interventions
Educational Intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

NCT04705415
Conditions
Healthy
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cypress, California
Conditions
Healthy Volunteer
Interventions
atirmociclib (PF-07220060)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Congenital Hyperinsulinism
Interventions
Cohort 1, Cohort 2, Cohort 3, Cohort 4
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
6
States / cities
Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
Conditions
Discoid Lupus
Interventions
CC-930, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Irvine, California • Washington D.C., District of Columbia + 15 more
Conditions
HIV Infections
Interventions
VH4527079
Biological
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Conditions
Multiple Myeloma
Interventions
TNB-383B
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
San Francisco, California • New Orleans, Louisiana • Rochester, Minnesota + 6 more
Conditions
Non-small Cell Lung Cancer Stage I
Interventions
Ad5-yCD/mutTKSR39rep-ADP Adenovirus
Biological
Lead sponsor
Benjamin Movsas, M.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Multisystemic Smooth Muscle Dysfunction Syndrome, ACTA2
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
29 Days and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Completed No phase listed Observational

Near Infrared Spectroscopy (St02)

NCT01062685
Conditions
Septic Shock
Interventions
Near-infrared spectroscopy assessment
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Interventions
Decitabine, Depsipeptide, Celecoxib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more